Immune Design Corp.

12 patents currently held · Updated Nov 15, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Jul 2030

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Jan 9, 2027
The maintenance fee for GLA monotherapy for use in cancer treatment (US 10,342,815) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
2 fees due Feb 27, 2027
1 fee due Sep 10, 2027
The maintenance fee for Multigenome retroviral vector preparations and methods and systems for producing and using same (US 10,584,356) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 8,187,872	Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein In force Ends no later than Jul 23, 2030 · From the USPTO record	In force	Ends no later than Jul 23, 2030	From the USPTO record
US 10,391,157	Materials and methods for producing improved lentiviral vector particles In force Ends no later than Mar 30, 2032 · From the USPTO record	In force	Ends no later than Mar 30, 2032	From the USPTO record
US 9,044,420	Immunogenic Compositions and Methods of Using the Compositions for Inducing Humoral and Cellular Immune Responses In force Term ends Apr 6, 2032 · High confidence	In force	Term ends Apr 6, 2032	High confidence
US 9,555,099	Vaccines for HSV-2 In force Term ends May 16, 2033 · From the USPTO record	In force	Term ends May 16, 2033	From the USPTO record
US 9,895,435	Vaccines for HSV-2 In force Ends no later than May 16, 2033 · From the USPTO record	In force	Ends no later than May 16, 2033	From the USPTO record
US 10,391,164	Vaccines for HSV-2 In force Ends no later than May 16, 2033 · From the USPTO record	In force	Ends no later than May 16, 2033	From the USPTO record
US 8,957,047	GLA monotherapy for use in cancer treatment In force Ends no later than Apr 18, 2034 · From the USPTO record	In force	Ends no later than Apr 18, 2034	From the USPTO record
US 8,962,593	GLA monotherapy for use in cancer treatment In force Ends no later than Apr 18, 2034 · From the USPTO record	In force	Ends no later than Apr 18, 2034	From the USPTO record
US 10,342,815	GLA monotherapy for use in cancer treatment In force Term ends Apr 18, 2034 · From the USPTO record	In force	Term ends Apr 18, 2034	From the USPTO record
US 10,993,956	GLA monotherapy for use in cancer treatment In force Term ends May 5, 2034 · From the USPTO record	In force	Term ends May 5, 2034	From the USPTO record

10 of 12 patents shown.

Pro members see all 12.

Pro members: see all 12 patents

Also on record, not counted in the 12: 5 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 abandoned · 15 no status recorded

List them